drugset
drugset / Trial / NCT03620201

M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer

NCT03620201 ↗

Phase 1 Completed 20 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies how well anti-PD-L1/TGFbetaRII fusion protein M7824 (M7824) works in treating patients with stage II-III HER2 positive breast cancer. Immunotherapy with M7824 may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Timeline

Start
2018-08-03
Primary completion
2024-10-18
Completion
2024-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Bintrafusp alfa Protein / enzyme biologic — Intravenous

Indications

female breast carcinoma